Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants

Ohlsson A, Walia R, Shah SS

Published Online:

April 14, 2010

A common complication for very preterm (premature) or very small babies is PDA (patent ductus arteriosus). PDA is an open channel between the lungs and heart. It should close after birth, but sometimes remains open because of the baby's premature stage of development. PDA can lead to life-threatening complications. The usual treatment for PDA is indomethacin, a drug that will successfully close the PDA in the majority of cases, but can cause serious adverse effects. Another option is the drug ibuprofen. This review of 20 trials including 1092 infants found that ibuprofen is as effective as indomethacin to close a PDA and causes fewer transient adverse effects on the kidneys and reduces the risk of necrotizing enterocolitis, a serious condition that affects the gut. Information on whether ibuprofen confers any important long-term advantages on development or not is not known. Long-term follow-up studies to 18 months of age and to the age of school entry are needed to decide whether ibuprofen or indomethacin is the drug of choice for closing a PDA.

Abstract (click to read)

Background:

Indomethacin is used as standard therapy to close a patent ductus arteriosus (PDA) but is associated with reduced blood flow to several organs. Ibuprofen, another cyclo-oxygenase inhibitor, may be as effective as indomethacin with fewer side effects.

Objectives:

To determine the effectiveness and safety of ibuprofen compared to placebo or no intervention for closing a PDA in preterm and/or low birth weight infants.
To determine the effectiveness and safety of ibuprofen compared to other cyclo-oxygenase inhibitors for closing a PDA in preterm and/or low birth weight infants.

Search strategy:

MEDLINE, EMBASE, The Cochrane Library, the reference lists of identified studies, meta-analyses and personal files were searched in December 2009.

Selection criteria:

Randomized or quasi-randomized controlled trials of ibuprofen for the treatment of a PDA in newborn infants.

Data collection and analysis:

Data collection and analysis conformed to the methods of the Cochrane Neonatal Review Group.

Main results:

Twenty studies are included in this review (6 studies added in this update). One study (n = 136) compared ibuprofen to placebo. Ibuprofen reduced the composite outcome of infant deaths, infants who dropped out or required rescue treatment [RR 0.58 (95% CI 0.38, 0.89); RD -0.22 (95% CI -0.38, -06); NNTB 5 (95% CI 3,17)]. Failure rates for PDA closure with ibuprofen compared to indomethacin was reported in 19 studies (n = 956 infants). There was no statistically significant difference between the groups [typical RR 0.94 (95% CI 0.76, 1.17)]; typical RD -0.02 (95% CI -0.07, 0.04); I2 = 0%]. The risk of developing necrotizing enterocolitis (NEC) was reduced for ibuprofen [15 studies (n = 865); typical RR 0.68 (95% CI 0.47, 0.99); typical RD -0.04 (95% CI -0.08, -0.00; (p = 0.04); NNTB 25 (95% CI 13, infinity); I2 = 0%]. There is less evidence of transient renal insufficiency in infants who receive ibuprofen compared to indomethacin. No other important differences were noted for common neonatal morbidities. Oro-gastric administration of ibuprofen appears as effective as i.v. administration.

Authors' conclusions:

Ibuprofen is effective in closing a PDA. Ibuprofen is as effective as indomethacin in closing a PDA and reduces the risk of NEC and transient renal insufficiency. Given the reduction in NEC noted in this update, ibuprofen currently appears to be the drug of choice. Studies are needed to evaluate the effect of ibuprofen compared to indomethacin treatment on longer term outcomes in infants with PDA.

This record should be cited as:

Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews 2010, Issue 4. Art. No.: CD003481. DOI: 10.1002/14651858.CD003481.pub4

Assessed as up to date:

February 28, 2010

Find the research

Get full text at The Cochrane Library

Primary Review Group:

Neonatal Group

Health topics:

Neonatal care > Patent ductus arteriosus

Cochrane Summaries^beta

Independent high-quality evidence for health care decision making

Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants

More like this

Copyright © 2012 - The Cochrane Collaboration